Search Results

HuidaGene Therapeutics and Synthego Corporation (“Synthego”), a leading provider of innovative CRISPR solutions for developing cell and gene therapies, proudly announce a partnered licensing agreement for the high-fidelity Cas12 CRISPR nuclease (hfCas12Max).

May 29, 2024

·

3 min read

Press Releases

Synthego and Vita Therapeutics Announce Strategic Licensing Agreement for hfCas12Max CRISPR Nuclease

April 8, 2025

·

2 min read

Biotech Bay

Synthego Announces CEO Transition to Focus on Enabling CRISPR Therapeutics

Synthego Corporation, a leading provider of genome engineering solutions, announced that Paul Dabrowski will step down as Chief Executive Officer, effective immediately.

March 27, 2024

·

3 min read

Press Releases

Synthego Signs Strategic Agreement with AstraZeneca to License CRISPR Gene Editing Enzyme

January 14, 2025

·

2 min read

Business

Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developers

Synthego and SeQure Dx have announced a strategic partnership to provide CRISPR-based therapeutics developers with comprehensive off-target editing analytical services that include best-in-class technology and turn-key end-to-end development solutions.

January 23, 2024

·

4 min read

Drug Development

Synthego Bridges Critical Preclinical Gap to Accelerate CRISPR-based Cell and Gene Therapies

Synthego, a leading provider of genome engineering solutions, announced the launch of its IND-enabling gRNAs, a transformative product offering that revolutionizes the CRISPR-based cell and gene therapy preclinical pipeline.

October 4, 2023

·

2 min read